Schwerdtle Patricia, Onekon Coretta-Kings, Recoche Katrina
1Nursing and Midwifery, Faculty of Medicine,Nursing, and Health Sciences,Monash University,Melbourne,Victoria,Australia.
3Cameroon Ministry for Health,Cameroon,Africa.
Prehosp Disaster Med. 2018 Feb;33(1):2-6. doi: 10.1017/S1049023X17007166. Epub 2018 Jan 10.
Introduction The efficacy of oral cholera vaccines (OCVs) in laboratory conditions has been established, and the World Health Organization (WHO; Geneva, Switzerland) has recommended their preventative use in high-risk settings. The WHO recommendation has not been fully operationalized, nor has it been extended to apply to the reactive use of OCVs in real field epidemic conditions due to concerns about potential resource diversion, feasibility, cost, and acceptability. The purpose of this study is to assess and synthesize existing evidence of OCV effectiveness when used reactively in real field conditions.
A systematic review and meta-analysis was conducted involving studies that investigated vaccine effectiveness when used as a reactive measure; that is, cases had reached epidemic threshold and a cholera epidemic was declared in real field epidemic conditions. OVID Medline (US National Library of Medicine, National Institutes of Health; Bethesda, Maryland USA), CINAHL (EBSCO Information Services; Ipswich, Massachusetts USA), and EMBASE (Elsevier; Amsterdam, Netherlands), along with grey literature, were systematically searched using pre-determined criteria. Two independent reviewers identified studies that met the selection criteria and data were extracted using validated tools. Pooled estimates were obtained using fixed effect models.
Of the 347 articles that met the inclusion criteria, four studies were retrieved for meta-analysis (three were case-control studies and one was a case-cohort study) involving a total of 1,509 participants and comprising 175 cases and 1,334 case controls. The effectiveness of one or two doses of either Shanchol (Shantha Biotechnics; India) or ORC-Vax (Vabiotech; Vietnam) OCVs showed a combined vaccine effectiveness of 75% (95% CI, 61-84).
A positive association was demonstrated between the reactive use of OCVs and protection against cholera. This supported the WHO recommendation to utilize OCVs reactively as an additional measure to the standard cholera epidemic response package. Schwerdtle P , Onekon CK , Recoche K . A quantitative systematic review and meta-analysis of the effectiveness of oral cholera vaccine as a reactive measure in cholera outbreaks. Prehosp Disaster Med. 2018;33(1):2-6.
引言 口服霍乱疫苗(OCV)在实验室条件下的有效性已得到证实,世界卫生组织(WHO;瑞士日内瓦)已建议在高风险环境中预防性使用。由于担心潜在的资源转移、可行性、成本和可接受性,WHO的这一建议尚未完全实施,也未扩展到适用于在实际现场疫情情况下OCV的应急使用。本研究的目的是评估和综合在实际现场条件下应急使用OCV时有效性的现有证据。
进行了一项系统评价和荟萃分析,纳入研究调查了疫苗作为应急措施使用时的有效性;即病例已达到流行阈值且在实际现场疫情情况下宣布霍乱疫情。使用预先确定的标准对OVID Medline(美国国立医学图书馆,美国国立卫生研究院;美国马里兰州贝塞斯达)、CINAHL(EBSCO信息服务公司;美国马萨诸塞州伊普斯维奇)和EMBASE(爱思唯尔;荷兰阿姆斯特丹)以及灰色文献进行系统检索。两名独立评审员确定符合入选标准的研究,并使用经过验证的工具提取数据。使用固定效应模型获得合并估计值。
在符合纳入标准的347篇文章中,检索到四项研究进行荟萃分析(三项为病例对照研究,一项为病例队列研究),共涉及1509名参与者,包括175例病例和1334例对照。单剂量或两剂量的Shanchol(印度Shantha生物技术公司)或ORC-Vax(越南Vabiotech公司)OCV的有效性显示联合疫苗有效性为75%(95%CI,61-84)。
证明了应急使用OCV与预防霍乱之间存在正相关。这支持了WHO关于将OCV作为标准霍乱疫情应对措施之外的一项额外措施进行应急使用的建议。施韦尔特勒P、奥内科恩CK、雷科切K。口服霍乱疫苗作为霍乱疫情应急措施有效性的定量系统评价和荟萃分析。院前灾难医学。2018;33(1):2-6。